Table 3.

Details of combined BAPN and AngII mouse TAD model

Mouse age (week)	Details of AngII infusion			Details of BAPN administration			TAD rates at the BAPN and AngII treatment end point	Reference
	Dose (ng/(kg∙min))	Route	Duration (week)	Dose (mg/(kg∙d))	Route	Duration (week)
5–6	1000	By pump	2	150.0	By pump	2	40.0% TAD; 50.0% TAR	Tomida et al., 2019
8	1000	By pump	4	150.0	By pump	2	25.0% TAR	Takayanagi et al., 2014
8	1000	By pump	4	150.0	By pump	2	52.4% AR	Kawai et al., 2017
8	1000	By pump	6	150.0	By pump	2	20.0% TAD/TAR	Hu et al., 2019
9	1000	By pump	6	150.0	By pump	2	2.2% TAD; 20.0% TAR	Kanematsu et al., 2010
10	1000	By pump	6	150.0	By pump	2	14.6% AR	Imanishi et al., 2018
10–12	1000	By pump	6	150.0	By pump	2	7.8% AD; 15.7% AR	Izawa-Ishizawa et al., 2019
13–15	1000	By pump	6	150.0	By pump	2	No death	Imanishi et al., 2016
7	1000	By pump	4	37.5	By pump	4	7.7% AD	Kurobe et al., 2013a
7	1000	By pump	4	32.5	By pump	4	5.6% AD	Kurobe et al., 2013b
8	1000	By pump	4	1 mg/mL*	In drinking water	2	16.7% TAR	Obama et al., 2015
8	1000	By pump	4	1 mg/mL	In drinking water	2	45.0% AR	Kawai et al., 2017
8	1000	By pump	4	1 mg/mL	In drinking water	2	15.0% AR	Suehiro et al., 2019

AD: aortic dissection; AngII: angiotensin II; AR: aortic rupture; BAPN: β-aminopropionitrile; TAD: thoracic aortic dissection; TAR: thoracic aortic rupture.

^*1 mg/mL≈20 mg/(kg∙d)